ChlodantaneХлодантан
N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.
What the studies found
Experiment described in a patent · 2019
Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
Study of multiple preparations
- Cold-exposure motor coordination
- 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) sp=0.04 versus cold control
- Sydnocarb comparator
- 6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiorityp=0.04
The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.
Study notes · methods, sources and limitations
Participants or model Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Design Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Important limitations
- Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure. The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product. The groups were small, and the source gives conflicting comparison-group sizes.
- These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.
RU2704126C2; filed 28 November 2016 · Patent report
Animal research · 2006
Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane
Study of multiple preparations
The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.
Study notes · methods, sources and limitations
Participants or model Experimental animal tissue-distribution study; human participants not reported.
Important limitations
- The accessible material is an introduction, conclusions and bibliography transcribed by a third party, not the complete dissertation. Concentration-time tables, half-lives and tissue-specific exposure estimates were not recovered. Occupational-use statements in the introduction concern actoprotectors collectively and do not document a Chlodantane-treated human cohort.
Candidate of Medical Sciences dissertation. Volgograd, 2006; 124 pages according to catalogue metadata · Dissertation abstract; third-party transcription
Animal research · 2023
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
Study of multiple preparations
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
Study notes · methods, sources and limitations
Participants or model Mouse pharmacology experiments
Important limitations
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety. An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose. The Russian and English versions are one publication, not independent replication.
Pharmaceutical Chemistry Journal. 57(4):523–534 · Publication record
About Chlodantane
Names in this research collection
ADK-910 · Chlondatane · Chlodantan
Identity / background source ↗
Research background
N-(adamantan-2-yl)-4-chlorobenzamide, an experimental benzamide from the Russian adamantane program. Its amide linkage distinguishes it from Bromantane’s arylamine.
Archival sources and remaining questions ↗
Clinical testing reported by Sirius University
Sirius University’s announcement of 21 February 2023 states that Chlodantane completed the necessary stages of clinical studies. This is a newly highlighted historical source, rather than an announcement of a new 2026 trial.
The announcement supplies no trial identifier, phase, participant count or clinical results. Its statement does not independently establish marketing authorization, human efficacy or safety.
Read the announcement translation and clinical-development history ↗
- Compound class
- Experimental adamantane / analogue
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Institutional statements describe clinical testing; no primary human-trial report verified
Study methods
Animal pharmacology, tissue-distribution research, chemical-method papers and historical documents
Independent replication
Independent replication not established; translations are not separate experiments
Source access
Access and review depth appear with each linked record
Safety evidence
Human safety and interactions not established; animal activity is not a safe-use recommendation
Open a topic for the evidence assessment.
Patents and claimed inventions
These 3 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2006
Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane
The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.
Study notes and original source
Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane
Experimental Chlodantane; source-specific preparation · Dissertation abstract; third-party transcription
Format: Dissertation abstract transcription · Reviewed: Author-abstract transcription: introduction, conclusions and bibliography checked; full dissertation not recovered
A. V. Safronenko · Candidate of Medical Sciences dissertation. Volgograd, 2006; 124 pages according to catalogue metadata
The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.
- Population / setting
- Experimental animal tissue-distribution study; human participants not reported.
- Source reviewed
- Author-abstract transcription: introduction, conclusions and bibliography checked; full dissertation not recovered
Study limitations
- The accessible material is an introduction, conclusions and bibliography transcribed by a third party, not the complete dissertation. Concentration-time tables, half-lives and tissue-specific exposure estimates were not recovered. Occupational-use statements in the introduction concern actoprotectors collectively and do not document a Chlodantane-treated human cohort.
Reviewed 2026-11-01.
Animal research · 2001
Toxicological characterization of new psychotropic drugs of the actoprotector and nootropic classes
The author reports that preclinical dossiers including Chlodantane, Bromantane and Bromitil were submitted to the Pharmacological Committee and supported recommendation for clinical investigation. The same work describes dose-dependent reproductive and blood-cell effects in animals.
Study notes and original source
Toxicological characterization of new psychotropic drugs of the actoprotector and nootropic classes
Experimental Chlodantane; source-specific preparation · Dissertation abstract; third-party transcription
Format: Dissertation abstract transcription · Reviewed: Third-party transcription of author-abstract sections and conclusions checked; full dissertation and committee dossier not recovered
L. I. Bugaeva · Doctor of Biological Sciences dissertation. Volgograd, 2001
The author reports that preclinical dossiers including Chlodantane, Bromantane and Bromitil were submitted to the Pharmacological Committee and supported recommendation for clinical investigation. The same work describes dose-dependent reproductive and blood-cell effects in animals.
- Population / setting
- Preclinical animal toxicology program; no human trial cohort documented in the accessible text.
- Source reviewed
- Third-party transcription of author-abstract sections and conclusions checked; full dissertation and committee dossier not recovered
Study limitations
- A statement about submission or recommendation is not the committee decision itself, a trial authorization number, evidence of administration to volunteers, or proof of completed clinical trials. Animal toxicology rankings do not establish human safety. Related reproductive publications may overlap this program.
Reviewed 2026-11-01.
Lab research · 2023
Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors
The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.
Study notes and original source
Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors
Cage-amide family; lead 18a distinct from Chlodantane; Bromantane also tested · Journal publication
E. S. Mozhaitsev, E. V. Suslov, D. A. Rastrepaeva, O. I. Yarovaya, S. S. Borisevich, E. M. Khamitov, D. S. Kolybalov, S. G. Arkhipov, N. I. Bormotov, L. N. Shishkina, O. A. Serova, R. V. Brunilin, A. A. Vernigora, M. B. Nawrozkij, A. P. Agafonov, R. A. Maksyutov, K. P. Volcho, N. F. Salakhutdinov · Viruses. 2023;15(1):29. PMID 36680072; PMCID PMC9865139
The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.
- Population / setting
- Cultured-cell antiviral and cytotoxicity comparisons of cage-amide compounds, with computational target modelling; no human participants.
- Source reviewed
- Original full-text XML reviewed via Europe PMC, including findings, tables and interpretation; procedural chemistry and virology are not reproduced here
Study limitations
- Cell-culture activity does not establish treatment benefit in people. Selectivity index compares cytotoxicity and antiviral concentrations in the assay; it is not a human therapeutic index. The strongest family result must not be transferred to Chlodantane. The paper does not substantiate the Sirius news release’s claim of historical human testing.
Reviewed 2026-11-01.
Laboratory analysis · 2025
A sustainable twist on the Ritter reaction: iron-based deep eutectic solvents as a green route to amide synthesis
The publication uses Chlodantane as a gram-scale demonstration of a reusable reaction medium for amide chemistry. It reports an 89% isolated yield for that demonstration and evaluates process sustainability. Its significance is continued chemical-method development and analytical characterization, rather than evidence of clinical effectiveness.
Study notes and original source
A sustainable twist on the Ritter reaction: iron-based deep eutectic solvents as a green route to amide synthesis
Chlodantane chemical-method demonstration; ADK code discrepancy noted · Journal publication
Luciana Cicco, Arfa Yousaf, Paola Vitale, Filippo Maria Perna, Vito Capriati · RSC Sustainability. 2025;3:4079–4086. First published 15 July 2025; CC BY 3.0
The publication uses Chlodantane as a gram-scale demonstration of a reusable reaction medium for amide chemistry. It reports an 89% isolated yield for that demonstration and evaluates process sustainability. Its significance is continued chemical-method development and analytical characterization, rather than evidence of clinical effectiveness.
- Population / setting
- Chemical synthesis and analytical characterization; no animal or human pharmacology experiment.
- Source reviewed
- Review based on the publisher abstract, citation and selected article passages. The full PDF was unavailable.
Study limitations
- The article labels the example ADK-919, whereas the historical Chlodantane records use ADK-910. That discrepancy is retained and ADK-919 is not adopted as a confirmed synonym. Chemical yield, purity and process reuse are not pharmacological efficacy or human safety outcomes.
Reviewed 2026-11-01.
Experiment described in a patent · 2019
Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.
Study notes and original source
Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
· RU2704126C2; filed 28 November 2016
The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.
Results and tables
Reported patent results
Reported findings
The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.
Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Population or model Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cold-exposure motor coordination | 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls | Medians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control |
| Sydnocarb comparator | 6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold control | Worse retention in this test; not general clinical inferiority · p=0.04 |
These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
- The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
- The groups were small, and the source gives conflicting comparison-group sizes.
Reviewed 2026-11-06.
Animal research · 2023
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
Study notes and original source
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
- Population / setting
- Mouse pharmacology experiments
- Source reviewed
- Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
- An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
- The Russian and English versions are one publication, not independent replication.
Reviewed 2026-10-03.
Laboratory analysis · 2019
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
Study notes and original source
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes
I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
- Population / setting
- Chemical synthesis and characterization; background pharmacology citations
- Source reviewed
- Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Study limitations
- Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
- ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.
Reviewed 2026-10-03.
Animal research · Year unconfirmed
Role of neurotropic adamantane-containing compounds in the regulation of immunity
The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
Study notes and original source
Role of neurotropic adamantane-containing compounds in the regulation of immunity
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
· Dissertation author’s abstract; third-party Russian transcription
The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
- Population / setting
- Multiple mouse strains and laboratory immune assays
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
- Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.
Reviewed 2026-10-03.
Animal research · 1996
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
Study notes and original source
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996
ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
- Population / setting
- Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
- Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.
Reviewed 2026-10-03.
Experiment described in a patent · 1996
Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation
The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.
Study notes and original source
Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation
· SU1646256A1
The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.
Results and tables
Reported patent results
Experimental results unavailable in the source
Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.
The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
Population or model The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Original experimental outcomes | Not available in the accessed bibliographic entry | No animal survival percentage or human performance effect is invented |
The original certificate is unavailable. Whether it contains experimental results remains unknown.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
- Source reviewed
- Bibliographic index entry accessed. No readable original experimental description or results tables were available; quantitative extraction requires the original publication.
Study limitations
- Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
- Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.
Reviewed 2026-11-06.
Experiment described in a patent · 2018
Phenoxyacetamide structural analogues of Chlodantane and ADK-918
The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.
Study notes and original source
Phenoxyacetamide structural analogues of Chlodantane and ADK-918
· RU2660654C1; Volgograd State Technical University
The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.
Results and tables
Reported patent results
Reported findings
The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.
Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
Population or model Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Analogue 1 recovery | 15.1 g, 85% yield | Manufacturing result for the newly claimed analogue, not Chlodantane or ADK-918 |
| Analogue 2 recovery | 80% yield; melting interval 94.5–95.0°C | A different new analogue; analytical characterization |
Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-11-06.
Laboratory analysis · 2019
Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction
Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.
Study notes and original source
Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction
· Zhurnal Organicheskoi Khimii. 55(11):1781–1788
Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
Review of earlier studies · 1999
Adamantane derivatives enhancing body's resistance to emergencies
Summarizes screening of adamantane derivatives and distinguishes Bromantane from the chemically different Chlodantane.
Study notes and original source
Adamantane derivatives enhancing body's resistance to emergencies
Morozov IS, Klimova NV, Sergeeva SA, Ivanova IA, Barchukov VG, Kovalev GI, Piatin BM, Avdiunina NI · Vestnik Rossiiskoi akademii meditsinskikh nauk (3):28-32. PMID 10222828
Summarizes screening of adamantane derivatives and distinguishes Bromantane from the chemically different Chlodantane.
- Population / setting
- Experimental adamantane-development program and animal stress models
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- A development-program summary is not an independent human trial.
- Historical claims about specific military deployments need their own contemporary documentation.
Reviewed 2026-09-29.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗